News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer 1/24/2017
Onxeo Release: Company Completes Enrollment In Phase 3 Study Of Livatag For The Treatment Of Hepatocellular Carcinoma 1/24/2017
Genentech (RHHBY) Release: FDA Grants Priority Review for Actemra to Treat Giant Cell Arteritis 1/24/2017
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 1/23/2017
Success of Pfizer (PFE)’s Humira Biosimilar for Rheumatoid Arthritis in Phase III Bodes Well for Its Strong Biosimilar Pipeline 1/23/2017
Actelion (ALIOF.PK) Release: Amid Takeover Talks With Johnson & Johnson (JNJ), The Company's Hypertension Drug Flunks Key Phase III Test 1/23/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Bristol-Myers Squibb (BMY) Release: Company Falls Behind Rival Merck & Co. (MRK), Will Not Pursue Faster Approval for Lung Cancer Combo 1/20/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: Companies' Psoriasis Drug Wows In Phase III Study, Eyes Q3 Filing 1/19/2017
Synthetic Biologics (SYN) Release: Company Confirms Key Features Of Pivotal Phase 2b/3 Trial Of SYN-010 Pursuant To Consultations With FDA 1/19/2017
Bristol-Myers Squibb (BMY) Release: Company's Opdivo (Nivolumab) Demonstrated Efficacy And Improved Survival In Patients With Previously Treated Advanced Gastric Cancer In A Randomized Phase III Study 1/19/2017
Zavante Therapeutics Release: Company Reports Completion Of Patient Treatment In The ZEUS Study Of ZTI-01 (fosfomycin for injection) For The Treatment Of Complicated Urinary Tract Infections 1/19/2017
ImmunoGen (IMGN) CEO Sees Potential in Company’s Lead ADC Product 1/18/2017
New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome 1/18/2017
How This Israeli Biotech Could be a Threat to Celgene (CELG) 1/18/2017
Jazz Pharma (JAZZ) Release: Company Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating Defibrotide For The Potential Prevention Of VOD In High Risk Patients 1/18/2017
Global Blood Therapeutics (GBT) Release: Company Announces Enrollment Of First Patient In Phase III HOPE Study In Sickle Cell Disease 1/18/2017
Paratek Pharma (PRTK) Release: Company Announces Completion Of Enrollment In Omadacycline Phase III Community-Acquired Bacterial Pneumonia Study 1/18/2017
Elite Pharma (ELI) Release; Company Reports Positive Topline Results From A Pivotal Bioequivalence Study For A Generic Oxycontin 1/17/2017
TetraPhase (TTPH) Doses First Patient In IGNITE3 Phase III Clinical Trial Of Once-Daily IV Eravacycline In cUTI 1/17/2017
AstraZeneca PLC (AZN) Release: Biopharma Rejigs Primary Endpoints for Mystic Lung Cancer Trial 1/17/2017
Alcobra (ADHD) Release: Company Stock Decimated As ADHD Drug Flunks Phase III Test 1/17/2017
Allergan (AGN), Gedeon Richter (RIG2.F) Release: Companies Show Off Late-Stage Uterine Fibroids Data 1/17/2017
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
New Spinraza Data Has Biogen (BIIB) Screaming 'It's Worth It!' 1/16/2017
JPM17: Opko Health (OPK) CEO's Gameplan After Its Recent Growth Hormone Failure 1/13/2017
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017
Shionogi Release: Pharma's Investigators are Prepping a FDA App for New Antibiotic After Positive Trial 1/13/2017
JPM17: New Biogen (BIIB) CEO on Groundbreaking Alzheimer's Trial and the Company's Future 1/12/2017
Advanced Accelerator Applications Release: Biotech Announces The New England Journal of Medicine Publication Of Lutathera NETTER-1 Phase III Results 1/12/2017
Trevena (TRVN) Release: Company Completes Phase 3 Apollo Trials For Oliceridine, Says Athena Study On Track 1/12/2017
Augmenix Release: Company Announces Positive Three-Year Long-Term Data Highlighting Benefits Of Spaceoar Hydrogel Spacer For Patients With Prostate Cancer 1/12/2017
Starpharma Release: VivaGel BV Granted QIDP And Fast Track Designation By U.S. FDA 1/12/2017
Keryx (KERX) Release: Biopharma Announces Publication Of Auryxia (Ferric Citrate) Phase III Trial Results For Iron Deficiency Anemia (IDA) In Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) In Journal Of The American Society Of Nephrology 1/12/2017
JPM17: Aurinia (AUPH)’s CEO on a Mission to Improve the Way Lupus Nephritis is Treated 1/11/2017
Vtesse Announces Dosing Of First Patient In Australia In Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 1/11/2017
Tonix Pharma (TNXP) Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference 1/11/2017
Amgen (AMGN) Release: Study Results Published In JAMA Show Company's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone In Adults With Secondary Hyperparathyroidism On Hemodialysis 1/11/2017
CytoDyn (CYDY) Release: Biotech Files For Breakthrough Therapy Designation With The FDA For PRO 140 In HIV Therapy 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Citius Pharma Release: Company's Mino-Lok Addresses Resistant Pathogens 1/11/2017
RedHill Biopharma (RDHL) Release: Pharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections 1/11/2017
TherapeuticsMD (TXMD) Release: Company Announces Publication Of Two Manuscripts On The Rejoice Trial For TX-004HR In Leading Peer-Reviewed Medical Journal 1/11/2017
NICO Corporation Release: Company Announces First Patient Enrolled In Phase 3 Randomized Controlled Trial On Early Intervention Of Hemorrhagic Stroke, Deadliest Form Of Stroke 1/10/2017
Pluristem Therapeutics (PSTI) Release: Jumps as the FDA Clears Critical Limb Ischemia Trial 1/10/2017
Halozyme (HALO) Release: Pharma Company Provides Program Updates, 2017 Financial Guidance At 35th Annual JP Morgan Healthcare Conference 1/10/2017
Valeant (VRX) Release: Pharma Company Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 1/10/2017
RedHill Biopharma (RDHL) Release: Pharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection 1/10/2017
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017
AbbVie (ABBV)'s HCV Drug Shows 99% Cure Rate In Study 1/9/2017
Lipocine (LPCN) Receives FDA Guidance On The Phase III Program For LPCN 1107, An Oral Alternative For The Prevention Of Preterm Birth 1/9/2017
Alcobra (ADHD) Provides Update On Recent FDA Meeting And Path Forward For MDX Clinical Development Program 1/9/2017
Adamas Pharma (ADMS) Outlines Key 2017 Priorities And Highlights 2016 Achievements 1/9/2017
Esperion (ESPR) Announces Initiation Of Three Pivotal Phase 3 Studies For Bempedoic Acid 1/9/2017
PTC Therapeutics (PTCT) Provides Corporate Update And Outlines 2017 Strategic Priorities To Maximize The Global Value Of Translarna And Advance Its Innovative Pipeline 1/9/2017
Enanta Pharmaceuticals, Inc. Announces High SVR12 Rates Achieved In Genotype 1 Chronic HCV Infected Japanese Patients With Eight Weeks Of Treatment With Abbvie’s Investigational, Pan-Genotypic, Ribavirin-Free Regimen Of Glecaprevir/Pibrentasvir (G/P) 1/9/2017
Incyte (INCY) And Merck & Co. (MRK) To Advance Clinical Development Program Investigating The Combination Of Epacadostat With KEYTRUDA (Pembrolizumab) 1/9/2017
Acceleron Pharma Outlines Corporate Goals And Priorities For 2017 1/6/2017
Alexion (ALXN) Release: FDA Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 1/6/2017
Orexigen (OREX) Announces Publication Of Contrave (Naltrexone Hcl And Bupropion Hcl Extended-Release Tablets) Real-World Study Results In "Obesity" 1/6/2017
CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 1/5/2017
Soligenix (SNGX) Receives Positive Scientific Advice From The EMA For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 1/5/2017
Otonomy (OTIC) Announces Positive Top-Line Results From Phase III Clinical Trial of OTIPRIO in Patients With Acute Otitis Externa 1/5/2017
Rigel (RIGL) Provides Business Updates And Preliminary Data In IgA Nephropathy 1/5/2017
Aevi Genomic Medicine Announces Completion Of Enrollment For Phase 2/3 SAGA Clinical Trial Of AEVI-001 (NFC-1) In mGluR+ ADHD Adolescents 1/5/2017
AEterna Zentaris (AEZS) Crashes on Disappointing Phase III Data 1/5/2017
Sun Pharma (SUNPHARMA.NS) Announces Positive Topline Results Of Confirmatory Phase-3 Clinical Trial For Seciera For Treatment Of Dry Eye 1/4/2017
FDA Grants Bayer (BAY) Priority Review For Stivarga (Regorafenib) For The Second-Line Systemic Treatment Of Liver Cancer 1/4/2017
CytRx (CYTR) Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas 1/4/2017
Trevena (TRVN) Completes Enrollment Of Phase III APOLLO Pivotal Efficacy Trials Of Oliceridine For Moderate-To-Severe Acute Pain 1/4/2017
NeuroRx Announces FDA IND Clearance For NRX-101 Phase 2b/3 Study And Publication Of Promising Biomarker Data 1/4/2017
Agile Therapeutics, Inc. Announces Positive Top-line Phase III Results 1/4/2017
Ocular Therapeutix (OCUL) Jumps on More Positive Study Data for Dextenza 1/4/2017
Inotek (ITEK) Plunges On Failed Phase III Glaucoma Trial 1/3/2017
Ardelyx (ARDX) Announces Initiation Of Two Clinical Trials For RDX7675 For Treatment Of Hyperkalemia 1/3/2017
Axsome (AXSM) Receives FDA Clearance Of IND For Phase II/III Trial Of AXS-05 In Alzheimer’s Disease Agitation 1/3/2017
TRACON Pharma (TCON) Receives Special Protocol Assessment (SPA) Agreement From FDA For Phase III Clinical Trial Of TRC105 In Angiosarcoma 1/3/2017
Dermira (DERM) Initiates Phase III Clinical Program In Acne 1/3/2017
Phase III Flop for Pfizer (PFE)'s Drug Partner Opko Health (OPK) 1/3/2017
4 Fatal Deaths in Seattle Genetics (SGEN)' Early-Stage Trials of AML Drug 12/30/2016
Anthera Pharma (ANTH) Plunges After Cystic Fibrosis Drug Fails Late-Stage Trial 12/29/2016
Galena Biopharma  (GALE) Stocks Jump After FDA Meeting, Blood Cancer Therapy GALE-401 to Enter Phase III 12/28/2016
The 7 Worst Clinical Disasters of 2016 12/27/2016
After Fraud Probe, Alexion (ALXN) Reports Failed Soliris Trial 12/27/2016
ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Designation In Europe For The Treatment Of Pancreatic Cancer 12/27/2016
International Myeloma Foundation Release: Landmark Study Published Today In The Lancet Shows Clear Myeloma Survival Benefit With Triple Drug Combination 12/27/2016
Portola (PTLA) Announces FDA Accepts New Drug Application For Priority Review And EMA Validates Marketing Authorization Application For Oral, Factor Xa Inhibitor Anticoagulant Betrixaban 12/27/2016
Progenics (PGNX) Announces Independent Committee’s Positive Recommendation For Continuation Of Phase 3 Clinical Trial Of SPECT/CT Imaging Agent 1404 12/27/2016
JAMA Publishes Mylan (MYL) And BioCon (BIOCON.NS)'s Proposed Biosimilar Trastuzumab Phase 3 Data 12/27/2016
Synergy Pharma Announces Positive Results In Second Phase 3 Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C) 12/27/2016
Chugai Pharma's Bispecific Antibody "Emicizumab" For Hemophilia A Meets Primary Endpoint In Phase lll Study 12/22/2016
Roche (RHHBY) Takes a Win as Emicizumab Hemophilia Drug Succeeds in Phase III 12/22/2016
New Trial Results Bolster Genentech (RHHBY)'s Chances of New MS Drug Approval 12/22/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Psoriatic Arthritis 12/22/2016
Janssen Biotech (JNJ) Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA (Golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis 12/21/2016
Antares Pharma (ATRS) Announces Submission Of New Drug Application For Quickshot Testosterone 12/21/2016
After Failed Phase III, Auven to Terminate the KIACTA Program 12/21/2016
Lexicon Pharma (LXRX) Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In Patients With Type 1 Diabetes 12/21/2016
Octapharma AG Presents Key Data With Nuwiq In Previously Untreated Patients From The Nuprotect Study At American Society of Hematology (ASH) Annual Meeting In San Diego, USA 12/21/2016
Eli Lilly (LLY) Joins cTAP, Helping To Accelerate Enriched Clinical Trial Design For The Provision Of New Treatments For Duchenne Muscular Dystrophy Patients 12/21/2016
Kiadis Pharma Provides Update On Second Dose Trial (CR-AIR-008) With ATIR101 12/21/2016
Akebia (AKBA) Forges $1B U.S. Deal with Otsuka Pharma on Late-Stage Drug 12/20/2016
Theravance Biopharma (TBPH) Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline (GSK) And Innoviva 12/20/2016
Janssen Sciences Ireland UC Release: Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen 12/20/2016
Amgen (AMGN) And UCB, Inc. (UCBJF.PK) Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan 12/20/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
Nabriva Achieves 60% Randomization Target In LEAP 1 Phase 3 Trial In Community Acquired Bacterial Pneumonia 12/20/2016
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex In The Treatment Of Endometriosis 12/20/2016
Primary Endpoint Met in ViiV Healthcare's Two Phase III Trials of Two-Drug HIV Treatment Regimen 12/20/2016
PHARNEXT Completes Patient Enrollment In International Pivotal Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 12/20/2016
TetraPhase (TTPH) Provides Regulatory And Clinical Update For Eravacycline 12/19/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index 12/19/2016
BrainStorm Cell Reports On Successful End Of Phase 2 Meeting With FDA, Upcoming Phase 3 Trial And Planned Application For Hospital Exemption For NurOwn 12/19/2016
Akcea Therapeutics, Ionis Pharma (IONS) Phase 3 COMPASS Met Primary Endpoint 12/19/2016
GlaxoSmithKline (GSK) Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma 12/19/2016
Tonix Pharma (TNXP)’s PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA 12/19/2016
Pfizer (PFE)'s Xtandi Flunks Late-Stage Study Against Johnson & Johnson (JNJ)'s Zytiga 12/16/2016
Janssen Biotech (JNJ) Submits Application Seeking FDA Approval Of STELARA (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis 12/16/2016
Grunenthal Receives Breakthrough Therapy Designation From U.S. FDA For Neridronic Acid For The Treatment Of CRPS 12/16/2016
Flamel Technologies (FLML) Doses First Patient In REST-ON Phase III Trial Of FT218 for Excessive Daytime Sleepiness & Cataplexy 12/16/2016
Catalyst Pharma (CPRX) Announces First Patient Enrolled In Second Phase III Trial Of Firdapse In Lambert-Eaton Myasthenic Syndrome (LEMS) 12/15/2016
Boehringer Ingelheim Release: Nintedanib Granted Orphan Drug Designation For Treatment Of Mesothelioma 12/15/2016
bluebird bio (BLUE) Announces First Patient Treated With LentiGlobin Drug Product In Northstar-2 (HGB-207) Phase III Trial Of Patients With Transfusion-Dependent ?-Thalassemia 12/14/2016
BioPharm Executive: So Long 2016 (and Good Riddance?) 12/14/2016
Proteon (PRTO)'s Kidney Drug Flunks Must-Pass Phase III Trial 12/13/2016
Ophthotech (OPHT) Plunges as Wet AMD Drug Combo Trials With Novartis AG (NVS) Flops in Phase III Studies 12/13/2016
Repros Therapeutics (RPRX) Requests Meeting With FDA To Discuss Phase III Requirements For Proellex In The Treatment Of Symptomatic Uterine Fibroids 12/13/2016
Paratek Pharma (PRTK) Advances Timing Of Top-Line Data For Phase III Community Acquired Bacterial Pneumonia Study To The Second Quarter Of 2017 12/13/2016
RedHill Biopharma (RDHL) Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease 12/13/2016
Ophthotech (OPHT) Announces Results From Pivotal Phase 3 Trials Of Fovista In Wet Age-Related Macular Degeneration 12/12/2016
3 Drugs Heading To The FDA Soon 12/12/2016
UroGen Announces FDA Acceptance Of Investigational New Drug Application For Mitogel, A Novel Sustained Release Formulation Of Mitomycin C, For The Treatment Of Low-Grade Upper Tract Urothelial Carcinoma 12/12/2016
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting 12/12/2016
CytoDyn (CYDY) Reports Treatment Of First Several Patients With PRO 140 In Its Phase III Monotherapy Trial For HIV 12/12/2016
As Biogen (BIIB)'s Drug Shines, Eli Lilly (LLY) Releases Detailed Results of Its Own Failure Solanezumab 12/9/2016
Galapagos (GLPG.BR) Release: Start Phase 2b/3 Study With Filgotinib In Ulcerative Colitis 12/9/2016
Cytokinetics (CYTK) Announces New Data Presented At The International Symposium On ALS/MND 12/9/2016
Synergy Pharma Announces Positive Results In First Phase III Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation (IBS-C) 12/9/2016
Alzheon Presents Analyses From Phase III Clinical Studies Showing Largest Clinical Effects Of Tramiprosate, The Active Molecule Of ALZ-801, In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease 12/9/2016
Novartis AG (NVS) LEE011 (Ribociclib) Plus Letrozole Analyses Show Superior PFS Across Broad Spectrum Of Patients In First-Line HR+/HER2- Advanced Breast Cancer Versus Letrozole 12/9/2016
AstraZeneca Canada (AZN) Release: Tagrisso (Osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer 12/9/2016
3 Biotechs That Could Peak in 2017 12/9/2016
Horizon Pharma (HZNP) Craters as Rare Neuromuscular Drug Flunks Late-Stage Study 12/8/2016
Dermira (DERM) Release: Second CIMZIA (Certolizumab Pegol) Phase III Trial Meets Co-Primary Efficacy Endpoints In Patients With Moderate-To-Severe Chronic Plaque Psoriasis 12/8/2016
Regeneron (REGN) And Sanofi (SNY)i Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA 12/8/2016
AstraZeneca PLC (AZN) Announces Subgroup Analysis From FALCON Trial Comparing FASLODEX (Fulvestrant) To ARIMIDEX (Anastrozole) 12/8/2016
Citius Pharma Moves Forward with Mino-Lok Phase 3 Trial 12/8/2016
Valeant (VRX) Announces Phase 3 Results For Psoriasis Treatment IDP-118 12/8/2016
4 Massachusetts Biotechs Making Waves at American Society of Hematology 12/7/2016
Advaxis (ADXS) To Present Data At Imvacs-Immunization And Vaccine Summit On Use Of Detoxified Listeriolysin O (dtLLO) As An Effective Adjuvant In Vaccine Formulations 12/7/2016
Revance (RVNC) Announces Initiation Of Subject Dosing In The SAKURA Phase III Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines 12/7/2016
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016
China-Prevalent Form Of NSCLC Responds To AstraZeneca PLC (AZN) Drug 12/7/2016
Merck & Co. (MRK) Release: KEYTRUDA (Pembrolizumab) Demonstrated Improved Health-Related Quality Of Life Compared To Chemotherapy In First-Line Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016
Repros Therapeutics (RPRX) Release: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism 12/7/2016
SAGE Therapeutics (SAGE) Soars on Expedited Development of SAGE-547 Following Meeting With the FDA 12/6/2016
Eisai Inc. (ESALF.PK) Announces Final Results From Phase 3 Open-Label Study Of Rufinamide At American Epilepsy Society Annual Meeting 12/6/2016
Resverlogix (RVX.TO) Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 12/6/2016
Sunesis (SNSS) Announces Presentation Of Updated Results From The VALOR Trial Examining Overall Survival In Patients Age 60 Years And Older With Relapsed/Refractory AML At The American Society of Hematology Annual Meeting 12/6/2016
Global Blood Therapeutics (GBT) Announces New Details On Its Novel Patient Reported Outcomes (PRO) Tool To Be Used In Phase III HOPE Study 12/6/2016
Novartis AG (NVS) Announces Zykadia First-Line Study Results Showing 16.6 Month Progression-Free Survival In Patients With ALK+ Advanced NSCLC 12/6/2016
Auris Med (EARS) On Track To Resume Enrollment Of Keyzilen Tinnitus Program Following Regulatory Feedback 12/6/2016
TherapeuticsMD (TXMD) Announces Positive Top-Line Results From Pivotal Phase 3 Replenish Trial In Postmenopausal Women With Moderate To Severe Vasomotor Symptoms (VMS) Treated With TX-001HR 12/6/2016
Celgene (CELG) Release: ABOUND Data Presented At The World Conference On Lung Cancer Further Explores Safety And Efficacy Of ABRAXANE For Challenging Patient Populations 12/6/2016
bluebird bio (BLUE) Provides Updates On HSC Gene Therapy Programs 12/6/2016
Eisai Inc. (ESALF.PK) Announces New Analyses And Data On Perampanel At American Epilepsy Society Meeting 12/6/2016
AstraZeneca PLC (AZN) Release: TAGRISSO (Osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer 12/6/2016
Top 7 Jaw-Dropping Pipeline Blowups This Year 12/5/2016
CSL Behring Presents New Phase III Analysis Of IDELVION For Hemophilia B At The 2016 American Society of Hematology Annual Meeting 12/5/2016
AOP Orphan Pharmaceuticals AG And PharmaEssentia Announce Pivotal Phase III Results For Ropeginterferon Alfa-2b In Polycythemia Vera At The American Society of Hematology Annual Meeting 2016 12/5/2016
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis And Long-Term RESONATE-2 Follow-Up Data At American Society of Hematology 2016 Show Lasting Efficacy 12/5/2016
Lipocine (LPCN) To Initiate Dosing Validation Study For LPCN 1021, Oral Testosterone Replacement Product Candidate 12/5/2016
Theravance Biopharma (TBPH) Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline (GSK) And Innoviva 12/5/2016
GW Pharma (GWPH) Announces New Epidiolex® (CBD) Positive Phase III Data In Dravet Syndrome And Lennox-Gastaut Syndrome 12/5/2016
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) 12/5/2016
Sanofi Genzyme (SNY) Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma 12/5/2016
Genentech (RHHBY)’s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan 12/5/2016
Incyte (INCY) Release: Pooled Analysis Of Five-Year Data From Two Phase 3 Studies Further Supports Overall Survival Advantage Observed In Patients With Myelofibrosis Treated With Jakafi (Ruxolitinib) 12/5/2016
Alexion (ALXN) Release: New Data From ALXN1210 Dose-Escalation Study Presented At American Society of Hematology Show Rapid And Sustained Reductions In LDH In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) 12/5/2016
Pfizer (PFE) And Avillion Announce Positive Top-Line Results For Phase III BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia 12/5/2016
Amgen (AMGN) And Allergan (AGN) Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab 12/2/2016
Shire (SHPG) Release: Topline Results Of Phase 3 Investigational Study Of VONVENDI [Von Willebrand Factor (Recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding And Blood Loss During Surgical Procedures 12/2/2016
Bay Area's Aradigm (ARDM) Stock Plunges After Posting Mixed-Data of Two Phase III Antibiotic Studies 12/1/2016
Amgen (AMGN) And Cytokinetics (CYTK) Release: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure 12/1/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia 12/1/2016
Cytokinetics (CYTK) Announces Start Of GALACTIC-HF, A Phase III Clinical Trial Of Omecamtiv Mecarbil 12/1/2016
GW Pharma (GWPH) Announces Epidiolex (Cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting 12/1/2016
Global Blood Therapeutics (GBT) Announces GBT440 Granted Orphan Drug Designation In Europe For Treatment Of Sickle Cell Disease 12/1/2016
Pfizer (PFE) Release: LYRICA (pregabalin) Phase III Trial In Pediatric Epilepsy Meets Primary Endpoint 12/1/2016
Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements In Erectile Function And Mood In Hypogonadal Men Treated With Natesto Nasal Testosterone Gel 11/30/2016
Nymox (NYMX) Reports Additional Positive Results From Completed Fexapotide BPH Phase III Studies Showing Significant Early Response And First-Line Efficacy 11/30/2016
Omeros (OMER) Release: International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury 11/30/2016
CytRx (CYTR) Reports Statistically Significant Updated Results From Pivotal Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcomas 11/29/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016
Vtesse Receives Rare Pediatric Disease Designation By The FDA For VTS-270 For The Treatment Of Niemann-Pick Type C1 Disease 11/29/2016
Nymox (NYMX) Reports Additional Positive Results From Completed Fexapotide BPH Phase III Studies Showing Significant Early Response And First-Line Efficacy 11/29/2016